Skip to main content

Advertisement

Table 1 Characteristics of the second series of participants with complicated vivax malaria: Amazonas, Brazil

From: DDX39B (BAT1), TNF and IL6 gene polymorphisms and association with clinical outcomes of patients with Plasmodium vivax malaria

    Clinical presentation at admission      
Patient no. Gender Age (years) Major manifestation Secondary manifestation Previous treatment Parasitaemia Disease duration (days) Haemoblogin (g/dL) Total bilirubin (μmol/L)
1 M 59 hyperbilirubinaemia   No 6,222 7 16.9 403.56
2 F 38 hyperlactemia   Yes 0 10 10.9 30.78
3 M 31 hyperbilirubinaemia   No 3,298 10 11.0 54.72
4 F 37 hyperbilirubinaemia   No 67,467 7 8.9 51.30
5 M 18 hyperbilirubinaemia   No 1,848 4 13.5 165.87
6 M 45 severe anaemia hyperbilirubinaemia No 243 10 6.5 138.51
7 F 40 severe anaemia   No 33,553 10 7.0 27.36
8 M 66 convulsion   Yes 185 14 13.0 *
9 M 17 hyperbilirubinaemia   No 226 6 11.9 53.01
10 M 31 hyperbilirubinaemia   No 5,937 15 13.5 165.87
11 M 1 severe anaemia   No 38,712 9 5.0 8.55
12 M 26 hyperbilirubinaemia   No 128 2 10.6 61.56
13 F 4 months convulsion prostration No 108,033 7 11.7 *
14 M 19 severe anaemia   No 0 17 6.5 15.39
15 M 50 respiratory failure   No 310 5 10.1 8.55
16 F 35 severe anaemia hyperbilirubinaemia No 34,673 1 4.8 138.51
17 F 41 respiratory failure   No 24,815 8 9.9 39.33
18 F 18 hyperbilirubinaemia   No 670 5 11.7 61.56
19 M 44 severe anaemia   Yes 0 7 6.9 13.68
20 F 23 severe anaemia   Yes 264 8 6.4 6.84
21 M 5 prostration   No 291 15 8.2 6.84
22 M 21 hyperbilirubinaemia   Yes 832 7 9.7 102.6
23 M 12 respiratory failure   Yes 0 6 7.8 15.39
24 F 74 respiratory failure   No 325 5 11.7 29.07
25 M 37 respiratory failure   Yes 0 10 7.1 17.10
26 F 26 hyperbilirubinaemia   No 254 9 11.3 140.22
27 M 53 hyperbilirubinaemia   No 45,833 6 11.8 59.85
28 F 36 hyperbilirubinaemia   No 0 3 7.9 85.50
29 F 15 severe anaemia   Yes 8,894 8 6.9 11.97
30 M 22 hyperbilirubinaemia   No 3,054 7 15.1 73.53
31 M 25 hyperbilirubinaemia   Yes 27,954 3 15.0 138.51
  1. Severe anaemia was defined as haemoglobin levels below 7 g/dL for adults and below 5 g/dL for children and hyperbilirubinaemia by serum total bilirubins >51.3 μmol/L. Respiratory failure was defined as tachypnea, shortness of breath, mental confusion clinical signs of hypoxaemia (central and/or peripheral cyanosis). Previous treatment indicates participants who already started malaria therapy before the blood sample collection. *Total bilirubin was not measured in these individuals.